GSK's malaria vaccine, Sanofi and Regeneron's Praluent win EU nods; India again rejects Roche's Valcyte patent claims;

@FiercePharma: India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Two Sandoz plants in Germany and 1 in India to be shuttered by Novartis next year. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind. Story | Follow @CarlyHFierce

> Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 drug, Praluent, has won a recommendation for European regulatory approval. Release

> GlaxoSmithKline's ($GSK) malaria vaccine, Mosquirix, has received a positive scientific opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). Release

> Indian authorities have for the second time rejected Roche's ($RHHBY) patent claims for Valcyte. Report

> Anthem ($WLP) said on Friday it would buy Cigna ($CI) in a deal valued at $54.2 billion to create the largest U.S. health insurer by membership. Report

> India's Lupin is buying U.S. peer GAVIS Pharmaceuticals for $880 million to revive U.S. growth. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Bard hit with FDA warning letter affecting its vena cava filters. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Stroke-fighting Watchman, SpyGlass endoscope fuel strong Q2 for Boston Sci. Article | Follow @VarunSaxena2

@EmilyWFierce: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid. Story

> Stryker: M&A still top priority for cash, but spent only $92M in first half on acquisitions. More

> ViewRay goes public via reverse merger, raises almost $77M since IPO cancellation. Article

> Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report

Biotech News

@FierceBiotech: Biogen targets new biotech deals after reporting sour numbers, R&D setbacks. More | Follow @FierceBiotech

@JohnCFierce: These days, when the FDA locks the door to a cancer drug, it's saying something -- $SNSS. Release | Follow @JohnCFierce

> Denali names Carole Ho its R&D head. Chutes & Ladders

> Neos pulls off a $72M IPO to push its ADHD drugs forward. Item

> Roche backs out of its $1B cancer deal with Molecular Partners. Report

And Finally... The U.S. could save up to $16 billion annually if it negotiated Medicare Part D prices with drugmakers, a new paper says. Paper (PDF)

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.